Not a good buy right now: price is in a clear downtrend (bearish moving averages + weakening MACD), and there are no Intellectia buy signals to override the technical weakness.
If you are impatient and want action today, the higher-probability move is to avoid new entries until it reclaims the pivot (~4.774) and holds above it; otherwise downside risk toward ~4.514 remains.
Fundamentals show strong YoY revenue growth and improving losses, but near-term price action suggests the market is not rewarding it yet.
Momentum: MACD histogram -0.0284 and negatively expanding → bearish momentum is strengthening, not stabilizing.
RSI (6): 33.654 → near oversold territory but still classified as neutral here; suggests a bounce is possible, but not confirmed.
Key levels:
Immediate support: S1 ~4.614 (current price 4.605 is slightly below/at this area), next support S2 ~4.514.
Resistance/pivot: Pivot ~4.774, then R1 ~4.934, R2 ~5.034.
Near-term pattern stats (similar candlesticks): modest expected week gain (+1.97%) but flat-to-negative over a month (-0.2%), aligning with a weak broader trend.
Market backdrop: S&P 500 down ~1.24% today, which can add pressure to risk assets and small/mid caps.
Positive Catalysts
may attract short-term dip buyers if it stabilizes and reclaims ~4.77.
Neutral/Negative Catalysts
Technical downtrend remains intact: bearish moving averages + deteriorating MACD imply higher likelihood of further downside before any sustained recovery.
Gross margin declined (60.5%, down YoY), which can weigh on the quality of growth.
No fresh news catalysts in the last week to shift sentiment or trigger a rerating.
Price targets have been cut across multiple firms, reflecting tempered near-term expectations.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 1.972M, up +55.77% YoY (strong top-line growth off a small base).
Profitability: Net income -23.58M, improved +38.23% YoY (still meaningfully loss-making).
EPS: -0.63, improved +26.00% YoY.
Gross margin: 60.5%, down -2.31% YoY (slight deterioration).
Pros: constructive long-term stance from some firms (Buy/Overweight) and recognition of early U.S. launch traction.
Cons: lowered targets + cautious framing (Neutral at Baird) imply execution/pace-of-ramp uncertainty and a slower path to meaningful financial inflection.
Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is 10.41 USD with a low forecast of 5.82 USD and a high forecast of 13 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is 10.41 USD with a low forecast of 5.82 USD and a high forecast of 13 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.590
Low
5.82
Averages
10.41
High
13
Current: 4.590
Low
5.82
Averages
10.41
High
13
Stifel
Jonathan Block
Buy
downgrade
$12 -> $11
AI Analysis
2026-01-29
Reason
Stifel
Jonathan Block
Price Target
$12 -> $11
AI Analysis
2026-01-29
downgrade
Buy
Reason
Stifel analyst Jonathan Block lowered the firm's price target on Nyxoah to $11 from $12 and keeps a Buy rating on the shares as part of the firm's Animal Health, Sleep, and Vision overview for 2026.
Baird
Neutral
downgrade
2025-12-16
Reason
Baird
Price Target
2025-12-16
downgrade
Neutral
Reason
Baird lowered the firm's price target on Nyxoah to EUR 5 from EUR 7 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NYXH
